# Recommendations for biomarker data collection in clinical trials by longevity biotechnology companies

## TL;DR

This paper suggests standardized ways to collect biomarker data in aging clinical trials to improve data quality and sharing.

## Contribution

The paper introduces new recommendations for consistent biomarker data collection in longevity clinical trials.

## Key findings

- Standardized biomarker data collection can improve validation and benchmarking in aging research.
- Shared tools and practices can enable better reuse of clinical trial data.
- Adopting these recommendations requires minimal additional effort but offers broad benefits.

## Abstract

Biomarkers of aging have the potential to transform geroscience clinical trials because of their broad applications in stratifying participants, prioritizing interventions, and monitoring responses to geroprotectors. As longevity biotechnology companies (LBCs) continue to plan and launch innovative clinical trials, standard practices in collecting data and applying biomarkers of aging will allow the field to support parallel and ongoing validation and benchmarking efforts for aging biomarkers. Moreover, defining best practices will ensure future reuse of valuable clinical data through pre-competitive alignment on shared tools. Here, we propose recommendations for such collections. We believe that wide adoption of these recommendations will allow LBCs to produce and leverage the highest quality data from their clinical trials, while also benefiting the geroscience field more broadly with minimal additional effort.